Holen Sie sich die Stockscreener-App
17.44
2.29%
0.39
Schlusskurs vom Vortag:
$17.05
Offen:
$16.95
24-Stunden-Volumen:
1.62M
Relative Volume:
0.61
Marktkapitalisierung:
$1.52B
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-5.8919
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
+4.93%
1M Leistung:
+14.74%
6M Leistung:
+63.76%
1J Leistung:
+11.79%
1-Tages-Spanne:
$16.75
$17.62
1-Wochen-Bereich:
$16.36
$18.00
52-Wochen-Spanne:
$8.58
$18.00
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Vergleichen Sie SNDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
17.44 | 1.48B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year HighHere's Why - MarketBeat
Is Syndax Pharmaceuticals Inc. stock poised for growthWeekly Trend Summary & Fast Entry High Yield Stock Tips - newser.com
How Syndax Pharmaceuticals Inc. (1T3) stock compares with tech leadersWeekly Trend Summary & Long Hold Capital Preservation Tips - newser.com
Syndax at Jefferies: Strategic Growth in Hematologic Therapies By Investing.com - Investing.com Canada
Is Syndax Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
How Syndax Pharmaceuticals Inc. (1T3) stock gains from tech spendingJuly 2025 Recap & Daily Price Action Insights - newser.com
Why (SNDX) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
How Syndax Pharmaceuticals Inc. (1T3) stock trades under stagflationJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Is Syndax Pharmaceuticals Inc. stock reversal real or fakeMarket Activity Recap & Daily Technical Forecast Reports - newser.com
What insider purchases suggest about Syndax Pharmaceuticals Inc. (1T3) stockQuarterly Portfolio Summary & Technical Confirmation Trade Alerts - newser.com
How Syndax Pharmaceuticals Inc. stock performs in stagflation2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
Published on: 2025-11-19 00:07:46 - newser.com
Knott David M Jr Has $3.30 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metrics2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Why ETFs are accumulating Syndax Pharmaceuticals Inc. (1T3) stockJobs Report & Weekly Breakout Opportunity Watchlist - newser.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Syndax Pharmaceuticals (SNDX): Assessing Value After Revuforj FDA Expansion and Revenue Surge - Yahoo Finance
Is it too late to sell Syndax Pharmaceuticals Inc.2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
How Syndax Pharmaceuticals Inc. stock performs in rate cut cyclesWeekly Trading Summary & Risk Controlled Stock Pick Alerts - newser.com
Campbell & CO Investment Adviser LLC Invests $439,000 in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains "Overweight" Rating - Finviz
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating - Insider Monkey
Using Ichimoku Cloud for Syndax Pharmaceuticals Inc. technicalsBond Market & Growth-Oriented Investment Plans - newser.com
Will Syndax Pharmaceuticals Inc. stock maintain momentum in 20252025 Earnings Surprises & Proven Capital Preservation Methods - newser.com
Fox Run Management L.L.C. Buys Shares of 18,363 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):